Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Meiragtx Holdings Plc (MGTX)

$20.38 0.24 (1.16%)

16:00 EST MGTX Stock Quote Delayed 15 Minutes

Volume:

Previous Close $20.38

Market Cap 554.01M

PE Ratio -

EPS -

Volume (Avg. Vol.) 108,400

Day's Range 20.21 - 21.34

52-Week Range 9.10 - 30.23

Dividend & Yield N/A (N/A)

MGTX Stock Predictions, Articles, and Meiragtx Holdings Plc News

From the Web

What Makes MeiraGTx Holdings PLC (MGTX) a Strong Momentum Stock: Buy Now?

From Zacks Investment Research Dec 24, 2019

Does MeiraGTx Holdings PLC (MGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

5 Biotech Stocks Set For Continued Rally In 2020

From Talk Markets Dec 16, 2019

With the advance in RNA interference and gene therapy and given the positive developments throughout 2019, the space has high scope of growth in 2020.

Meiragtx Holdings (MGTX) Receives a Rating Update from a Top Analyst

From Analyst Ratings Dec 16, 2019

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Meiragtx Holdings (MGTX – Research Report), with a price target of $45.00. The company’s shares closed last Monday at $21.02. According to TipRanks.com, Amusa is a top 100 analyst with an average return of 27.9% and a 52.9% success rate.

5 Biotech Stocks Set for Continued Rally in 2020

From Zacks Investment Research Dec 16, 2019

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

Gene Therapy the Next Best Thing: Here's Why (Revised)

From Zacks Investment Research Dec 5, 2019

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Gene Therapy the Next Best Thing: Here's Why

From Zacks Investment Research Dec 4, 2019

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy